Literature DB >> 22235047

Systemic lupus erythematosus following HPV immunization or infection?

H F Soldevilla1, S F R Briones, S V Navarra.   

Abstract

BACKGROUND AND
PURPOSE: The link between autoimmunity and infectious agents has been strongly suggested by reports of lupus or lupus-like syndromes following immunization. This report describes three patients with either newly diagnosed systemic lupus erythematosus (SLE) or SLE flare, following vaccination for human papilloma virus (HPV). CASE 1: A 17-year-old female completed two doses of HPV vaccine uneventfully. Two months later, she developed arthralgias with pruritic rashes on both lower extremities, later accompanied by livedo reticularis, bipedal edema with proteinuria, anemia, leucopenia, hypocomplementemia and high titers of anti-nuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA). Kidney biopsy showed International Society of Nephrology/Renal Pathology Society Class III lupus nephritis. She was started on high dose steroids followed by pulse cyclophosphamide therapy protocol for lupus nephritis, and subsequently went into remission. CASE 2: A 45-year-old housewife, previously managed for 11 years as having rheumatoid arthritis, had been in clinical remission for a year when she received two doses of HPV immunization. Four months later, she developed fever accompanied by arthritis, malar rash, oral ulcers, recurrent ascites with intestinal pseudo-obstruction, and behavioral changes. Cranial MRI showed vasculitic lesions on the frontal and parietal lobes. Laboratory tests showed anemia with leucopenia, hypocomplementemia, proteinuria, ANA positive at 1:320, and antibodies against dsDNA, Ro/SSA, La/SSB and histone. She improved following pulse methylprednisolone with subsequent oral prednisone combined with hydroxychloroquine. CASE 3: A 58-year-old housewife diagnosed with SLE had been in clinical remission for 8 years when she received two doses of HPV immunization. Three months later, she was admitted to emergency because of a 1-week history of fever, malar rash, easy fatigability, cervical lymph nodes, gross hematuria and pallor. Laboratory exams showed severe anemia, thrombocytopenia, active urine sediments, and hypocomplementemia. Despite pulse steroid therapy, blood transfusions, intravenous immunoglobulin and aggressive resuscitative measures, she expired a day after hospital admission.
SUMMARY: These cases narrate instances of the onset or exacerbation of lupus following HPV immunization suggesting adjuvant-induced autoimmunity. On the other hand, there are reports of higher incidence of HPV infection in SLE, with the infection per se possibly contributing to disease activity. Thus, the benefit of HPV immunization may still outweigh the risk among these individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22235047     DOI: 10.1177/0961203311429556

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  33 in total

Review 1.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

2.  Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.

Authors:  Erin Y Liu; Leah M Smith; Anne K Ellis; Heather Whitaker; Barbara Law; Jeffrey C Kwong; Paddy Farrington; Linda E Lévesque
Journal:  CMAJ       Date:  2018-05-28       Impact factor: 8.262

Review 3.  Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction.

Authors:  Yahel Segal; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2018-03-05       Impact factor: 11.530

4.  HPV and systemic lupus erythematosus: a mosaic of potential crossreactions.

Authors:  Yahel Segal; Shani Dahan; Michele Calabrò; Darja Kanduc; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 5.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

6.  Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?

Authors:  Candace H Feldman; Seoyoung C Kim
Journal:  Expert Rev Vaccines       Date:  2014-06-17       Impact factor: 5.217

7.  Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry.

Authors:  Mojca Bizjak; Or Bruck; Sonja Praprotnik; Shani Dahan; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 8.  Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology.

Authors:  Claudia Müller-Ladner; Ulf Müller-Ladner
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

Review 9.  Safety of human papillomavirus vaccines: a review.

Authors:  Kristine K Macartney; Clayton Chiu; Melina Georgousakis; Julia M L Brotherton
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 10.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.